Merck-U02-Substudy 02C_Neoadjuvant_Melanoma - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if different combinations of experimental drugs are safe and effective treatments to give people before and after surgery to remove melanoma.
Melanoma
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with stages IIIB, IIIC, or IIID melanoma
- Have melanoma that can be treated with surgery
For more information about who can be in this study, please contact the study team at ivy.belskie@duke.edu.
What is Involved?
The study is divided into two periods: a screening period and a study dosing period.
If you choose to join this study, during the screening period you will:
- Have physical exams
- Have blood draws
- Have other tests done to assess your eligibility
If you are found to be eligible, you will continue on to the study dosing period. During this period, you will:
- Be randomly assigned (by chance, like taking numbers from a hat) to 1 of 3 groups
-- Group 1 will be treated with pembrolizumab and MK-7684 before surgery, and then pembrolizumab alone after surgery
-- Group 2 will be treated with pembrolizumab and V937 before surgery, and then pembrolizumab alone after surgery
-- Group 2 will be treated with only pembrolizumab before and after surgery
Study Details
